Citations

Clear

4206 citation(s) found for "Chen, Yu".

Human Immunodeficiency Virus Type 1 Vpr-Mediated G2 Arrest Requires Rad17 and Hus1 and Induces Nuclear BRCA1 and γ-H2AX Focus Formation
Zimmerman, Erik S., Andersen, Joshua L. , Ardon, Orly , DeHart, Jason L. , Blackett, Jana, Choudhary, Shailesh K. , Camerini, David , Nghiem, Paul , Planelles, Vicente , Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | October 14, 2004 | Volume: 24 | Issue: 21 | Pages: 9286-9294

10.1128/mcb.24.21.9286-9294.2004 | PMID 15485898 Get It

DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains
Yu, Xiaochun , Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | October 13, 2004 | Volume: 24 | Issue: 21 | Pages: 9478-9486

10.1128/mcb.24.21.9478-9486.2004 | PMID 15485915 Get It

Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest
Sengupta, Sagar , Robles, Ana I. , Linke, Steven P. , Sinogeeva, Natasha I., Pedeux, Rémy , Ward, Irene M., Celeste, Arkady, Nussenzweig, André , Halazonetis, Thanos D. , Harris, Curtis C. , Zhang, Ran , Chen, Junjie

Mayo Clinic

The Journal of Cell Biology | September 13, 2004 | Volume: 166 | Issue: 6 | Pages: 801-813

10.1083/jcb.200405128 | PMID 15364958 Get It

Bloom's syndrome is a rare autosomal recessive genetic disorder characterized by chromosomal aberrations, genetic instability, and cancer predisposition, all of which may be the result of abnormal signal transduction during DNA damage recognition. Here, we show that BLM is an intermediate responder to stalled DNA replication forks. BLM colocalized and physically interacted with the DNA damage response proteins 53BP1 and H2AX. Although BLM facilitated physical interaction between p53 and 53BP1, 53BP1 was required for efficient accumulation of both BLM and p53 at the sites of stalled replication. The accumulation of BLM/53BP1 foci and the physical interaction between them was independent of γ-H2AX. The active Chk1 kinase was essential for both the accurate focal colocalization of 53BP1 with BLM and the consequent stabilization of BLM. Once the ATR/Chk1- and 53BP1-mediated signal from replicational stress is received, BLM functions in multiple downstream repair processes, thereby fulfilling its role as a caretaker tumor suppressor.
Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the β-Blocker Evaluation of Survival Trial
Krause‐Steinrauf, Heidi , Nuzzo, Rebecca, Liang, Chang‐seng , Lowes, Brian D. , Hattler, Brack , Abraham, William T. , Olson, L., Krueger, Steven K. , Thaneemit-Chen, Surai, Hare, John, Loeb, Henry S., Domański, Mikołaj , Eichhorn, Eric J., Zelis, Robert, Lavori, Philip W., Bristow, Michael R. , Lindenfeld, JoAnn

Mayo Clinic

Circulation | August 31, 2004 | Volume: 110 | Issue: 11 | Pages: 1437-1442

10.1161/01.cir.0000141297.50027.a4 | PMID 15337700 Get It

Background— Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results— Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant ( P <0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group-dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions— In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.
Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States
Pool, Vitali , Braun, M. Miles, Kelso, John M. , Mootrey, Gina T., Chen, Robert T. , Yunginger, John W., Gargiullo, Paul, Team, the VAERS, Jacobson, Robert M. , Team, the VAERS

Mayo Clinic

Pediatrics | August 14, 2004 | Volume: 110 | Issue: 6 | Pages: e71-e71

10.1542/peds.110.6.e71 | PMID 12456938 Get It

Objective. Anaphylaxis after immunization, although rare, is serious and potentially life-threatening. Understanding risk factors for this reaction is therefore important. Gelatin is added to many vaccines as a heat stabilizer. Japanese researchers have demonstrated a strong association between immediate hypersensitivity reactions to measles, mumps, rubella, varicella, and Japanese encephalitis immunizations and subsequent detection of anti-gelatin immunoglobulin E (IgE) antibodies. They suggested that previous receipt by these patients of diphtheria-tetanus-acellular pertussis vaccines with trace amounts of gelatin was responsible for the sensitization. We aimed to assess whether a similar association exists for vaccinees in the United States who reported anaphylaxis after receipt of measles-mumps-rubella (MMR) or measles vaccines and to review recent trends in reporting of hypersensitivity reactions. Methods. We conducted a retrospective case-control study. Cases of anaphylaxis that met a predefined case definition were identified from the US Vaccine Adverse Event Reporting System (VAERS). Mayo Clinic patients who received MMR vaccine uneventfully served as controls. The study subjects were interviewed to obtain the history of allergies. Sera from study subjects and their matched controls were tested for IgE antibodies to gelatin, whole egg, and vaccine viral antigens using solid-phase radioimmunoassay. Data from the Biologics Surveillance System on annual numbers of doses of MMR and varicella vaccines distributed in the United States were used to evaluate possible changes in reporting of selected allergic adverse events. Results. Fifty-seven study subjects were recruited into the study and interviewed. Of these, 22 provided serum samples for IgE testing. Twenty-seven subjects served as a comparison group and provided a sample for IgE testing; 21 of these completed an allergy history questionnaire. Self-reported history of food allergies was present more frequently in the interviewed study subjects than in the controls, whereas the proportions of people with other characteristics were similar in both groups. None of the interviewed people had a history of food allergy to gelatin. The level of anti-gelatin IgE antibodies was significantly higher among study subjects than among controls, whereas the levels of IgE antibodies against egg and all 3 viral antigens did not differ significantly. Of 22 study subjects, 6 (27%) tested positive for anti-gelatin IgE, whereas none of the 27 controls did. The rate of anaphylactic reactions reported to VAERS after measles virus-containing immunization in the United States between 1991 and 1997 is 1.8 per 1 million doses distributed. No substantial increase in the number of reported allergic events after frequently used gelatin containing MMR and varicella vaccines could be observed during the first 4 years (1997–2000) since the introduction of diphtheria-tetanus-acellular pertussis vaccines for use in infancy. Conclusion. Anaphylactic reactions to MMR in the United States are rare. The reporting rate has the same order of magnitude as estimates from other countries. Almost one fourth of patients with reported anaphylaxis after MMR seem to have hypersensitivity to gelatin in the vaccine. They may be at higher risk of developing anaphylaxis to subsequent doses of other gelatin-containing vaccines. These people should seek an allergy evaluation before such immunization.
Quantifying elasticity and viscosity from measurement of shear wave speed dispersion
Chen, Shigao , Fatemi, Mostafa , Greenleaf, James F. , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | June 3, 2004 | Volume: 115 | Issue: 6 | Pages: 2781-2785

10.1121/1.1739480 | PMID 15237800 Get It

The propagation speed of shear waves is related to frequency and the complex stiffness (shear elasticity and viscosity) of the medium. A method is presented to solve for shear elasticity and viscosity of a homogeneous medium by measuring shear wave speed dispersion. Harmonic radiation force, introduced by modulating the energy density of incident ultrasound, is used to generate cylindrical shear waves of various frequencies in a homogeneous medium. The speed of shear waves is measured from phase shift detected over the distance propagated. Measurements of shear wave speed at multiple frequencies are fit with the theoretical model to solve for the complex stiffness of the medium. Experiments in gelatin phantoms show promising results validated by an independent method. Practical considerations and challenges in possible medical applications are discussed.
53BP1 is required for class switch recombination
Ward, Irene M., Reina‐San‐Martin, Bernardo , Olaru, Alexandru, Minn, Kay, Tamada, Koji , Lau, Julie S., Cascalho, Marília , Nussenzweig, André , Livák, Ferenc , Nussenzweig, Michel C. , Nussenzweig, André , Chen, Lieping , Chen, Junjie

Mayo Clinic

The Journal of Cell Biology | May 24, 2004 | Volume: 165 | Issue: 4 | Pages: 459-464

10.1083/jcb.200403021 | PMID 15159415 Get It

53BP1 participates early in the DNA damage response and is involved in cell cycle checkpoint control. Moreover, the phenotype of mice and cells deficient in 53BP1 suggests a defect in DNA repair (Ward et al., 2003b). Therefore, we asked whether or not 53BP1 would be required for the efficient repair of DNA double strand breaks. Our data indicate that homologous recombination by gene conversion does not depend on 53BP1. Moreover, 53BP1-deficient mice support normal V(D)J recombination, indicating that 53BP1 is not required for “classic” nonhomologous end joining. However, class switch recombination is severely impaired in the absence of 53BP1, suggesting that 53BP1 facilitates DNA end joining in a way that is not required or redundant for the efficient closing of RAG-induced strand breaks. These findings are similar to those observed in mice or cells deficient in the tumor suppressors ATM and H2AX, further suggesting that the functions of ATM, H2AX, and 53BP1 are closely linked.
Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin’s Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494)
Lee, Sandra, Chen, Michael G., Nazeer, Tipu, Einzig, Avi I., Ambinder, Richard F. , Henry, David H., Manalo, Jane, Li, Tianhong , Roenn, Jamie H. Von, Sparano, Joseph A. , Lee, Sandra, Ambinder, Richard F

Mayo Clinic

Journal of Clinical Oncology | April 15, 2004 | Volume: 22 | Issue: 8 | Pages: 1491-1500

10.1200/jco.2004.08.195 | PMID 15084622 Get It

Purpose To determine the effectiveness of an infusional chemotherapy regimen in patients with HIV-associated lymphoma treated before and after the use of highly active antiretroviral therapy (HAART) in routine clinical practice. Patients and Methods Ninety-eight assessable patients with HIV-associated intermediate- or high-grade non-Hodgkin’s lymphoma received cyclophosphamide 200 mg/m2/d, doxorubicin 12.5 mg/m2/d, and etoposide 60 mg/m2/d (CDE) given by continuous intravenous infusion for 4 days (96 hours) every 4 weeks plus filgrastim. Concurrent antiretroviral treatment consisted of the nucleoside analog didanosine in the first 43 patients enrolled before December 1996 (pre-HAART group), or HAART in the remaining 55 patients enrolled after that time (HAART group). Results Complete response occurred in 44 patients (45%; 95% CI, 35% to 55%). Failure-free survival and overall survival (OS) at 2 years was 36% (95% CI, 26% to 46%) and 43% (95% CI, 33% to 53%), respectively. At the time of the analysis, 30% in the pre-HAART group were alive compared with 47% in the HAART group; when adjusted for varying length of follow-up, patients in the HAART group had improved OS (P = .039). Patients in the HAART group experienced less grade 4 nonhematologic toxicity (22% v 42%; P = .037), thrombocytopenia (31% v 52%; P = .033), and anemia (9% v 27%; P = .021), and had fewer treatment-associated deaths (0% v 10%; P = .013). Conclusion Infusional CDE is an effective and potentially curative regimen for patients with HIV-associated lymphoma. Patients treated in the HAART era have less chemotherapy-associated toxicity and improved survival.
A kinematic method to calculate the workspace of the trapeziometacarpal joint
Kuo, Li‐Chieh , Cooney, W.P., Chen, Qingshan , Kaufman, Kenton R. , Su, Fong‐Chin , An, Kai‐Nan, Kaufman, Kenton R

Mayo Clinic

Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine | April 6, 2004 | Volume: 218 | Issue: 2 | Pages: 143-149

10.1243/095441104322984031 | PMID 15116901 Get It

The specific aim of this study was to develop a quantitative method and a kinematic method to evaluate the maximal workspace of the trapeziometacarpal (TM) joint. Six fresh-frozen human cadaver hands were disarticulated 4 cm proximal to the wrist joint and used in this experiment. The three-dimensional motion data of the TM joint was collected by an electromagnetic tracking device at 30 Hz. The workspace was reconstructed according to a complete set of motion data included circumduction, flexion-extension and abduction-adduction. A spherical fitting technique was used to obtain a sphere encompassing all the motion trajectories and estimating the centre of the sphere. The surface area of the maximal TM workspace, located on the one part of the sphere surface, was calculated by surface integration. The interclass correlation coefficient values for the reliability estimation of the repeated measurements of the radius and surface area of all specimens were 0.91 and 0.98 respectively. The mean coefficients of variance of the measured radius and the surface area were 2.04 per cent and 3.65 per cent respectively. The results also showed that using a spherical model to calculate the maximal workspace as an index for assessing TM joint impairment is practical.
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
Loprinzi, Charles L. , Sargent, Daniel J. , Thomé, Stephan D. , Haller, Daniel G. , Benedetti, Jacqueline, Francini, Guido, Shepherd, Lois E. , Seitz, Jean François, Labianca, Roberto , Chen, Wei , Cha, Stephen S., Heldebrant, Michael P., Goldberg, Richard M. , Gill, Sharlene , Alberts, Steven R. , Cha, Stephen S., Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | April 5, 2004 | Volume: 22 | Issue: 10 | Pages: 1797-1806

10.1200/jco.2004.09.059 | PMID 15067028 Get It

Purpose Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain. Patients and Methods Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis based on a Cox proportional hazards regression model. Treatment, age, sex, tumor location, T stage, nodal status, and grade were tested for both prognostic and predictive significance. Model derived estimates of 5-year disease-free survival and overall survival (OS) for surgery alone and surgery plus FU-based therapy were calculated for a range of patient subsets. Results Nodal status, T stage, and grade were the only prognostic factors independently significant for both disease-free survival and OS. Age was significant only for OS. In a multivariate analysis, adjuvant therapy showed a beneficial treatment effect across all subsets. Treatment benefits were consistent across sex, location, age, T-stage, and grade. A significant stage by treatment interaction was present, with treatment benefiting stage III patients to a greater degree than stage II patients. Conclusion Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade. Model estimates of survival stratified by T stage, nodal status, grade, and age are available at http://www.mayoclinic.com/calcs . This information may improve patients' and physicians' understanding of the potential benefits of adjuvant therapy.